Profile data is unavailable for this security.
About the company
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.
- Revenue in USD (TTM)90.22m
- Net income in USD-22.66m
- Incorporated2003
- Employees159.00
- LocationAlimera Sciences IncSTE 290, 6120 WINDWARD PARKWAYALPHARETTA 30005United StatesUSA
- Phone+1 (678) 990-5740
- Fax+1 (678) 990-5744
- Websitehttps://alimerasciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mediwound Ltd | 19.85m | -12.75m | 182.42m | 100.00 | -- | 8.04 | -- | 9.19 | -1.38 | -1.38 | 2.15 | 2.44 | 0.303 | 5.64 | 5.07 | 198,510.00 | -19.46 | -24.48 | -25.65 | -32.92 | 16.92 | 43.27 | -64.24 | -38.43 | 1.83 | -- | 0.218 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
Elite Pharmaceuticals Inc | 56.63m | 20.11m | 195.52m | 64.00 | 9.76 | 3.56 | 9.10 | 3.45 | 0.0197 | 0.0197 | 0.0554 | 0.0539 | 0.9093 | 2.69 | 5.02 | 884,767.80 | 32.29 | 19.07 | 38.79 | 24.29 | 46.55 | 46.63 | 35.51 | 20.77 | 2.08 | 1.70 | 0.1399 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
ASP Isotopes Inc | 1.27m | -19.62m | 201.75m | 76.00 | -- | 14.14 | -- | 158.44 | -0.5335 | -0.5335 | 0.0344 | 0.2164 | 0.0425 | -- | -- | 16,755.00 | -65.49 | -- | -81.59 | -- | 32.81 | -- | -1,542.66 | -- | -- | -17.39 | 0.633 | -- | -- | -- | -229.34 | -- | -- | -- |
Inhibrx Biosciences Inc | 1.78m | -271.16m | 206.28m | 166.00 | -- | 60.65 | -- | 115.69 | -5.35 | -5.35 | 0.0358 | 0.235 | 0.0066 | -- | 7.51 | 10,740.96 | -99.40 | -77.06 | -123.13 | -93.91 | -- | -- | -15,116.15 | -1,590.91 | -- | -12.67 | 0.9474 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
Greenwich Lifesciences Inc | 0.00 | -9.24m | 206.60m | 3.00 | -- | 40.33 | -- | -- | -0.719 | -0.719 | 0.00 | 0.3977 | 0.00 | -- | -- | 0.00 | -106.03 | -36.43 | -109.97 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
Zevra Therapeutics Inc | 28.01m | -50.90m | 262.42m | 65.00 | -- | 5.38 | -- | 9.37 | -1.34 | -1.34 | 0.7513 | 1.17 | 0.2172 | -- | 3.47 | 430,876.90 | -39.48 | -32.11 | -47.94 | -39.89 | 51.11 | -- | -181.75 | -128.42 | -- | -- | 0.4683 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
CorMedix Inc | 0.00 | -50.24m | 265.45m | 82.00 | -- | 4.58 | -- | -- | -0.9291 | -0.9291 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -78.96 | -54.84 | -88.88 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.41 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
Procaps Group SA | 414.10m | 52.20m | 269.65m | 5.50k | 4.59 | 6.85 | 3.87 | 0.6512 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
Sanara Medtech Inc | 68.00m | -4.89m | 273.42m | 107.00 | -- | 6.31 | -- | 4.02 | -0.5873 | -0.5873 | 8.15 | 5.02 | 1.04 | 1.99 | 8.63 | 635,556.60 | -7.68 | -17.73 | -9.30 | -22.07 | 88.80 | 88.08 | -7.39 | -17.13 | 1.02 | -9.21 | 0.184 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
Alimera Sciences Inc | 90.22m | -22.66m | 293.38m | 159.00 | -- | 7.21 | -- | 3.25 | -1.57 | -1.57 | 2.42 | 0.7762 | 0.8989 | 7.11 | 3.43 | 567,415.10 | -21.34 | -19.08 | -25.84 | -27.37 | 86.52 | 86.80 | -23.74 | -19.55 | 2.51 | -0.0756 | 0.6323 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
Aquestive Therapeutics Inc | 51.50m | -28.77m | 303.16m | 135.00 | -- | -- | -- | 5.89 | -0.4273 | -0.4273 | 0.7836 | -0.4012 | 0.5398 | 2.78 | 6.49 | 381,496.30 | -30.15 | -76.63 | -43.46 | -123.85 | 60.23 | 64.24 | -55.85 | -102.95 | 5.85 | -3.51 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
Scilex Holding Co | 47.05m | -160.60m | 309.83m | 106.00 | -- | -- | -- | 6.59 | -1.28 | -1.28 | 0.3905 | -1.79 | 0.5307 | 5.53 | 1.92 | 448,047.60 | -121.78 | -- | -- | -- | 66.14 | -- | -229.47 | -- | 0.1356 | -12.49 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
Verrica Pharmaceuticals Inc | 8.91m | -80.74m | 318.15m | 100.00 | -- | 210.98 | -- | 35.70 | -1.75 | -1.75 | 0.1929 | 0.0356 | 0.1321 | -- | 2.33 | 89,130.00 | -119.66 | -55.75 | -142.98 | -78.33 | 79.63 | -- | -905.83 | -754.94 | 3.04 | -21.71 | 0.9678 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
Jasper Therapeutics Inc | 0.00 | -63.93m | 325.24m | 45.00 | -- | 2.87 | -- | -- | -5.60 | -5.60 | 0.00 | 7.51 | 0.00 | -- | -- | 0.00 | -48.30 | -- | -51.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
Xeris Biopharma Holdings Inc | 171.36m | -64.40m | 376.57m | 377.00 | -- | -- | -- | 2.20 | -0.4648 | -0.4648 | 1.24 | -0.0619 | 0.5209 | 0.838 | 5.02 | 454,525.20 | -19.58 | -43.60 | -25.58 | -56.57 | 82.90 | 78.23 | -37.58 | -143.08 | 1.81 | -2.04 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
Holder | Shares | % Held |
---|---|---|
Caligan Partners LPas of 21 Jun 2024 | 16.84m | 32.14% |
Velan Capital Investment Management LPas of 14 May 2024 | 9.43m | 18.00% |
Stonepine Capital Management LLCas of 31 Mar 2024 | 4.05m | 7.73% |
Boothbay Fund Management LLCas of 31 Mar 2024 | 3.20m | 6.11% |
Altium Capital Management LPas of 31 Mar 2024 | 2.55m | 4.87% |
Clearline Capital LPas of 31 Mar 2024 | 2.09m | 3.98% |
AIGH Capital Management LLCas of 31 Mar 2024 | 1.52m | 2.90% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.03m | 1.97% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 494.28k | 0.94% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 470.57k | 0.90% |